GlassScriptPhysician profile
Cody Michael Browning
NPI 1316470495
$4,616.63
in general payments reported to CMS, 2019-2025
20 companies · $2,406 in 2025
The $2,406 reported for 2025 was more than what 91% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $2,211 · 2025: $2,406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,617.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,616.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $883.28 | 2024-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $489.66 | 2024-2025 | Rexulti |
| Tris Pharma INC | $470.42 | 2024-2025 | Dyanavel Xr, Onyda Xr |
| Abbvie INC. | $374.90 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $314.25 | 2024-2025 | Spravato, Invega Sustenna |
| Bausch Health US, LLC | $266.62 | 2024-2025 | Aplenzin, Wellbutrin |
| Axsome Therapeutics, INC. | $264.68 | 2024-2025 | Auvelity |
| Lundbeck LLC | $225.29 | 2024-2025 | Rexulti |
| Noven Therapeutics, LLC | $211.00 | 2024-2025 | Xelstrym |
| Supernus Pharmaceuticals, INC. | $210.03 | 2025 | Qelbree |
| Corium, LLC | $167.50 | 2024-2025 | Azstarys |
| Neurocrine Biosciences, INC. | $146.65 | 2024-2025 | Ingrezza |
| Ironshore Pharmaceuticals INC. | $146.21 | 2024 | |
| Collegium Pharmaceutical, INC. | $119.15 | 2025 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $111.03 | 2024-2025 | Trintellix |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $83.93 | 2024-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $45.97 | 2024-2025 | Austedo Xr, Austedo Xr |
| Idorsia Pharmaceuticals US INC | $37.50 | 2024 | Quviviq |
| Alkermes, INC. | $24.52 | 2025 | Aristada, Lybalvi |
| Tempus Ai, INC | $24.04 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cody Browning listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.